Preview

Вестник трансплантологии и искусственных органов

Расширенный поиск

ПРИМЕНЕНИЕ ЭВЕРОЛИМУСА У DE NOVO РЕЦИПИЕНТОВ ПОЧЕЧНОГО ТРАНСПЛАНТАТА

https://doi.org/10.15825/1995-1191-2010-2-74-81

Полный текст:

Аннотация

В последние годы выживаемость реципиентов ренальных трансплантатов и трансплантированных почек значительно улучшилась, однако долгосрочная выживаемость почечных трансплантатов практически не изменилась. Одним из важнейших факторов развития поздней дисфункции ренального трансплантата яв- ляется нефротоксичность ингибиторов кальциневрина. Эверолимус, новый препарат класса ингибиторов пролиферативного сигнала, позволяет минимизировать экспозицию циклоспорина А, а также обладает противоопухолевым действием. Данная статья представляет собой обзор литературных данных, касаю- щихся клинических аспектов применения эверолимуса у de novo реципиентов ренального трансплантата. 

Об авторе

Е. И. Прокопенко
ГУ «Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского», Москва
Россия


Список литературы

1. ANZDATA Registry Report 2004 // Australia and New Zealand Dialysis and Transplant Registry. Ed. McDo- nald S., Excell L. Adelaide, Australia.

2. Bohler T., Waiser J., Budde K. et al. The in vivo effect of rapamycin derivate SDZ RAD on lymphocyte prolifera- tion // Transplant. Proc. 1998. Vol. 30. P. 2195–2197.

3. Budde K., Lehne G., Winkler M. et al. Influence of ever- olimus on steady-state pharmacokinetics of cyclosporine in maintenance renal transplant patients // J. Clin. Phar- macol. 2005. Vol. 45(7). P. 781–791.

4. Certican® Summary of Product Characteristics, 2006.

5. Cоhen B., Smits J.M., Haase B. et al. Expanding the donor pool to increase renal transplantation // Nephrol.

6. Dial. Transplant. 2005. Vol. 20. P. 34–41.

7. Fritsche L., Horstrup J., Budde K. et al. Old-for-old kid- ney allocation allows successful expansion of the donor and recipient pool // Am. J. Transplant. 2003. Vol. 3.

8. P. 1434–1438.

9. Goudar R.K., Shi Q., Hjelmeland M.D. et al. Combination

10. therapy of inhibitors of epidermal growth factor receptor/ vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) of- fers improved glioblastoma tumor growth inhibition // Mol. Cancer. Ther. 2005. Vol. 4. P. 101–112.

11. Hoyer P.F., Ettenger R., Kovarik J.M. et al. Everolimus in pediatric de novo renal transplant patients // Trans- plantation. 2003. Vol. 75. P. 2082–2085.

12. Kauffman H.M., Cherikh W.S., Cheng Y. et al. Main- tenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies// Transplantation. 2005. Vol.80. P. 883–889.

13. Keown P. Improving quality of life. The new target for transplantation // Transplantation. 2001. Vol. 72 (12). P. S67–74.

14. Kirchner I.G., Meier-Wiedenbach I., Manns M.P. Clini- cal pharmacokinetics of everolimus // Clin. Pharmacol. 2004. Vol. 43 (2). P. 83–95.

15. Kolhe N., Mamode N., Van der Walt J., Pattison J. Re- gression of post-transplant Kaposi’s sarcoma using siro- limus // Int. J. Clin. Pract. 2006. Vol. 60 (11). P. 1509– 1512.

16. Kovaric J.M., Curtis J.J., Hricik D.E. et al. Differential pharmacokinetic interaction of tacrolimus and cyclo- sporine on everolimus // Transplant. Proc. 2006. Vol. 38 (10). P. 3456–3458.

17. Kovaric J.M., Kahan B.D., Kaplan B. et al. Longitudinal assessment of everolimus in de novo renal transplant re- cipients over the first post-transplant year: pharmacoki- netics, exposure-response relationships, and influence

18. on cyclosporine // Clin. Pharmacol. Ther. 2001. Vol. 69.

19. P. 48–56.

20. Kovaric J.M., Kalbag J., Figueiredo J. et al. Differential

21. influence of two cyclosporine formulations on everoli- mus pharmacokinetics: a clinically relevant pharmacoki- netic interaction // J. Clin. Pharmacol. 2002. Vol. 42. P. 95–99.

22. Krieger N.R., Becker B.N., Heisey D.M. et al. Chronic allograft nephropathy uniformly affects recipients of cadaveric, nonidentical living-related and living-unre- lated grafts // Transplantation. 2003. Vol. 75. P. 1677– 1682.

23. Lebbé C., Euvrard S., Barrou B. et al. Sirolimus conver- sion for patients with posttransplant Kaposi’s sarcoma // Am. J. Transplant. 2006. Vol. 6 (9). P. 2164–2168.

24. Lorber M.I., Mulgaonkar S., Butt K.M.H. et al. Everoli- mus versus mycophenolate mofetil in the prevention of rejection in de novo renal transplant recipients: a 3-year randomized, multicenter, phase III study // Transplanta- tion. 2005. Vol. 80. P. 244–252.

25. Lorber M.I., Ponticelli C., Whelchel J. et al. Therapeutic drug monitoring for everolimus in kidney transplanta- tion using 12-month exposure, efficacy and safety data // Clin. Transplant. 2005. Vol. 19. P. 145–152.

26. Majewski M., Korecka M., Joergensen J. et al. Immu- nosuppressive TOR kinase inhibitor everolimus (RAD) suppresses growth of cells derived from posttransplant lymphoproliferative disorder at allograft-protecting do- ses // Transplantation. 2003. Vol. 75. P. 1710–1717.

27. Majewski M., Korecka M., Kossev P. et al. The immuno- suppressive macrolide RAD inhibits growth of human Epstein-Barr virus-transformed B lymphocytes in vitro and in vivo: a potential approach to prevention and tre- atment of posttransplant lymphoproliferative disorders // Proc. Natl. Acad. Sci. USA. 2000. Vol. 97. P. 4285– 4290.

28. Majumder P.K., Febbo P.G., Bikoff R. et al. mTOR in- hibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1- dependent pathways // Nat. Med. 2004. Vol. 10. P. 594– 601.

29. Meier-Kriesche H.U., Schold J.D., Kaplan B. Long- term renal allograft survival: have we made significant progress or is it time to rethink our analytic and thera- peutic strategies? // Am. J. Transplant. 2004. Vol. 4 (8). P. 1289–1295.

30. Morrissey P.E., Gohh R., Yango A. et al. Renal transplant survival from older donors: a single center experience // Arch. Surg. 2004. Vol. 139. P. 384–389.

31. Nankivell B.J., Borrows R.J., Fung C.L. et al. The natu- ral history of chronic allograft nephropathy // N. Engl. J. Med. 2003. Vol. 349. P. 2326–2333.

32. Nashan B. The role of Certican (everolimus, RAD) in the many pathways of chronic rejection // Transplant. Proc. 2001. Vol. 33. P. 3215–3220.

33. Nashan B., Curtis J.J., Ponticelli C. et al. Everolimus and reduced-exposure cyclosporine in de novo renal- transplant recipients: a three-year phase II, randomized, multicenter, open-label study // Transplantation. 2004. Vol. 78. P. 1332–1340.

34. Pascual J., Boletis I.N., Campistol J.M. Everolimus (Certican®) in renal transplantation: a review of trial data, current usage and future directions // Transplant. Rev. 2006. Vol. 20. P. 1–18.

35. Pascual J., Cambi V., Dissegna D. et al. Efficacy and safety of 2 doses of everolimus combined with reduced dose Neoral in de novo kidney transplant recipients: 24 month analysis // Am. J. Transplant. 2005. Vol. 5 (Suppl. 11). Р. A1010.

36. Pascual J., Marcen R., Ortuno J. Clinical experience with everolimus (Certican) in elderly recipients: the «old-for-old» concept // Transplantation. 2005. Vol. 79. P. S85–S88.

37. Ponticelli C. Reducing exposure to calcineurin inhibitors following renal transplantation: clinical experience with everolimus (Certican) // Transplantation. 2005. Vol. 79. P. S69–S71.

38. Racusen L.C., Solez K., Colvin R.B. Fibrosis and atrophy in the renal allograft: interim report and new directions // Am. J. Transplant. 2002. Vol. 2. P. 203–206.

39. Rapamune® Summary of Product Characteristics, 2007.

40. Schuurman H.J., Cotton S., Fuchs S. et al. SDZ RAD, a new rapamycin derivate: Synergism with cyclosporine //

41. Transplantation. 1997. Vol. 64. P. 32–35.

42. Schuurman J.J., Ringers J., Schuler W. et al. Oral effica-

43. cy of the macrolide immunosuppressant SDZ RAD and of cyclosporine microemulsion in cynomolgus monkey kidney transplantation // Transplantation. 2000. Vol. 69. P. 737–742.

44. Serkova N., Jacobsen W., Niemann C.U. et al. Siroli- mus, but not the structurally related RAD (everolimus), enhances the negative effects of cyclosporine on mito- chondrial metabolism in the rat brain // Br. J. Pharmacol. 2001. Vol. 133. P. 875–885.

45. Serkova N., Litt L., James T.L. et al. Evaluation of indivi- dual and combined neurotoxicity of the immunosuppres-

46. sants cyclosporine and sirolimus by in vitro multinuclear NMR spectroscopy // J. Pharmacol. Exp. Ther. 1999. Vol. 289. P. 800–806.

47. Serkova N., Litt L., Leibfritz D. et al. The novel immu- nosuppressant SDZ RAD protect rat brain slices from cyclosporine-induced reduction of high-energy phos- phates // Br. J. Pharmacol. 2000. Vol. 129. P. 485–492.

48. Smits J.M., Persijn G.G., van Houwelingen H.C. et al. Evaluation of the Eurotransplant Senior Program. The results of the first year // Am. J. Transplant. 2002. Vol. 2. P. 664–670.

49. Stallone G., Schena A., Infante B. et al. Sirolimus for Ka- posi’s sarcoma in renal-transplant recipients // N. Engl. J. Med. 2005. Vol. 352 (13). P. 1317–1323.

50. Tedesco-Silva H. Jr., Vitko S., Pascual J. et al. 2306 and 2307 study groups. 12-month safety and efficacy of ever- olimus with reduced exposure cyclosporine in de novo renal transplant recipients // Transpl. Int. 2007. Vol. 20 (1). P. 27–36.

51. Vitko S., Margreiter R., Weimar W. et al. Everolimus (Certican) 12-month safety and efficacy versus myco- phenolate mofetil in de novo renal transplant recipients // Transplantation. 2004. Vol. 78. P. 1532–1540.

52. Vitko S., Margreiter R., Weimar W. et al. Three-year effi- cacy and safety results from a study of everolimus versus mycophenolate mofetil in de novo renal transplant pa- tients // Am. J. Transplant. 2005. Vol. 5. P. 2521–2530.

53. Vitko S., Tedesco H., Eris J. et al. Everolimus with opti- mized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studies // Am. J. Transplant. 2004. Vol. 4. P. 626–635.

54. Wolfe R.A., Ashby V.B., Milford E.L. et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cada- veric transplant // N. Engl. J. Med. 1999. Vol. 341 (23). P. 1725–1730.


Для цитирования:


Прокопенко Е.И. ПРИМЕНЕНИЕ ЭВЕРОЛИМУСА У DE NOVO РЕЦИПИЕНТОВ ПОЧЕЧНОГО ТРАНСПЛАНТАТА. Вестник трансплантологии и искусственных органов. 2010;12(2):74-81. https://doi.org/10.15825/1995-1191-2010-2-74-81

For citation:


Prokopenko E.I. EVEROLIMUS IN DE NOVO RENAL TRANSPLANT RECIPIENTS. Russian Journal of Transplantology and Artificial Organs. 2010;12(2):74-81. (In Russ.) https://doi.org/10.15825/1995-1191-2010-2-74-81

Просмотров: 258


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1995-1191 (Print)
ISSN 2412-6160 (Online)